Braidwell LP Krystal Biotech, Inc. Transaction History

Braidwell LP

$1.63 Billion
Q1 2025

A detailed history of Braidwell LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Braidwell LP holds 400,744 shares of KRYS stock, worth $50.8 Million. This represents 4.43% of its overall portfolio holdings.

Number of Shares

400,744

Previous 200,500 99.87%

Holding current value

$50.8 Million

Previous $31.4 Million 130.04%

% of portfolio

4.43%

Previous 1.76%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$142.64 - $194.44 $28.6 Million - $38.9 Million	200,244 Added 99.87%	400,744 $72.3 Million
Q4 2024 Feb 14, 2025	BUY	$156.64 - $199.61 $4.98 Million - $6.35 Million	31,809 Added 18.86%	200,500 $31.4 Million
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $10.7 Million - $13.1 Million	61,512 Added 57.39%	168,691 $30.7 Billion
Q2 2024 Aug 14, 2024	SELL	$153.12 - $183.64 $10.7 Million - $12.8 Million	-69,910 Reduced 39.48%	107,179 $19.7 Billion
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $2.06 Million - $3.43 Million	-19,111 Reduced 9.74%	177,089 $31.5 Billion
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $11.4 Million - $15.2 Million	118,703 Added 153.17%	196,200 $24.3 Billion
Q3 2023 Nov 14, 2023	SELL	$108.51 - $130.22 $17.8 Million - $21.3 Million	-163,902 Reduced 67.9%	77,497 $8.99 Billion
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $8.37 Million - $13.9 Million	-106,637 Reduced 30.64%	241,399 $28.3 Billion
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $725,347 - $844,385	-10,020 Reduced 2.8%	348,036 $27.9 Billion
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $22.6 Million - $28.6 Million	358,056 New	358,056 $28.4 Billion

Others Institutions Holding KRYS

# of Institutions

328

Shares Held

24.3M

Call Options Held

299K

Put Options Held

97.6K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.25B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.

Account